Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
800.00    36.00 (4.71%)
Bid:
791.00
Ask:
829.00
Spread: 38.00 (4.804%)
Market Cap: £54.40m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Investor presentations

26 Sep 2017 07:00

RNS Number : 7722R
Silver Falcon PLC
26 September 2017
 

Silver Falcon Plc

(to become Hemogenyx Pharmaceuticals Plc)

 

Investor presentations

 

Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited ("Hemogenyx"), announces that it will be holding a series of meetings with investors regarding the opportunity presented to shareholders by the proposed acquisition of Hemogenyx LLC ("Hemogenyx").

 

The presentation will be led by Chief Executive Officer & Co-Founder of Hemogenyx, Dr Vladislav Sandler, with other Proposed Directors available for discussions after the formal presentation. The same presentation will be given at all events which are being held at different times to offer convenient options for those wishing to attend.

 

3 October 2017 - Lunchtime presentation hosted by Peterhouse Corporate Finance Limited

Time:

12.30pm - a sandwich lunch will be provided

Location:

3rd Floor New Liverpool House, 15 Eldon Street, London EC2M 7LD

 

3 October 2017 - Afternoon Presentation hosted by Shard Capital Partners LLP

Time:

5pm - the presentation will be followed by drinks and canapes

Location:

23rd Floor, 20 Fenchurch Street, London EC3M 3BY

 

4 October 2017 - Evening presentation hosted by Optiva Securities Limited

Time:

6pm - the presentation will be followed by drinks and canapes

Location:

Sartoria, 20 Savile Row, London W1S 3PR

 

 

For more information on the proposed acquisition see the Latest News section on: www.silverfalconplc.com

 

For a short video by Dr Sandler on Hemogenyx click here: www.brrmedia.co.uk/event/160159

 

If you would like to register for any of the investor presentations, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com ensuring you detail in your email which presentation you would like to attend.

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Peter Redmond, Director

Via Walbrook PR

 

 

Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 

 

 

 

Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar

 

 

 

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

 

 

Flowcomms IR

Mob: +44 (0)7891 627 441 or sasha@flowcomms.com

Sasha Sethi

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAFNSALLXEAF
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
29th May 20269:18 amRNSGrant of Options and Extension of Warrant Term
30th Apr 20264:04 pmRNSFinal Results
28th Apr 20267:00 amRNSInstitutional Fundraise
14th Apr 20267:00 amRNSAnnual IND Report with FDA
31st Mar 20261:22 pmRNSTech Transfer Completion and Clinical Trial Update
27th Feb 20268:10 amRNSTotal Voting Rights
24th Feb 20267:00 amRNSHolding(s) in Company
23rd Feb 20267:00 amRNSExercise of Warrants and Issue of Equity
10th Feb 20263:52 pmRNSIssue of Equity - Correction
10th Feb 20267:00 amRNSIssue of Equity
30th Jan 20267:00 amRNSTotal Voting Rights
12th Jan 20267:00 amRNSHolding(s) in Company
22nd Dec 20258:00 amRNSUpdate on Admission of Shares
18th Dec 20257:00 amRNSIssue of Equity
8th Dec 202512:48 pmRNSHolding(s) in Company
28th Nov 20257:00 amRNSTotal Voting Rights
19th Nov 202511:47 amRNSPublication of Prospectus
29th Oct 20257:00 amRNSClinical Trial Update and Grant of Share Awards
6th Oct 20257:00 amRNSClearance to Initiate Pediatric Enrolment
30th Sep 20257:00 amRNSHalf-year Report
30th Sep 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSHemogenyx Signs Letter of Intent
18th Sep 20251:16 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSThird Patient Safety
11th Sep 20257:00 amRNS-RInvitation to Participate at DCNY Summit
8th Sep 20257:00 amRNSManufacturing Partnership with Made Scientific
5th Sep 20257:00 amRNSExercise of Warrants and Issue of Equity
3rd Sep 20251:57 pmRNSExercise of Warrants and Issue of Equity
1st Sep 20253:06 pmRNSIssue of convertible loan notes
29th Aug 20257:00 amRNSResult of Audit Tender
26th Aug 202511:44 amRNSHemogenyx raises £570,000 and Director's Dealing
15th Aug 20257:00 amRNSThird Patient Treated with HG-CT-1 CAR-T Therapy
31st Jul 20257:00 amRNSTotal Voting Rights
29th Jul 20258:00 amRNSPlacing to Raise £250,000 and Director’s Dealing
16th Jul 20257:00 amRNSHemogenyx Awarded Grant
30th Jun 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSClearance to Proceed with Pediatric Expansion
3rd Jun 20252:02 pmRNSPlacing to Raise £451,250 and Director’s Dealing
3rd Jun 20257:00 amRNSSecond Patient Passes Initial Safety Tests
30th May 20253:14 pmRNSTotal Voting Rights
29th May 20252:06 pmRNSResult of AGM
14th May 20257:00 amRNS-RPediatric Amendment to Clinical Protocol
13th May 20257:00 amRNSAGM Correction
8th May 20257:00 amRNSPlacing to Raise £451,250 and Director’s Dealing
2nd May 20254:24 pmRNSNotice of AGM
2nd May 20257:00 amRNSSecond Patient Treated with HG-CT-1 CAR-T Therapy
28th Apr 20257:00 amRNSFinal Results
3rd Apr 20257:00 amRNS-RFDA Annual Report
31st Mar 20257:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.